Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Prostate cancer screening in a Saudi population: an explanatory trial study

Abstract

The aim of this study is to explore the actual situation of prostate cancer in a cohort of healthy population in Saudi Arabia and to show the feasibility of screening for this disease using the internationally agreed criteria. This study was conducted in the city of Riyadh, in the outpatient clinics of four different health facilities. All men presented to the outpatient clinics during the period of study, from January 2008 to December 2008, were invited to participate in the study, in which they were subjected to PSA blood testing and digital rectal examination (DRE). When either test was abnormal, transrectal ultrasound and multiple prostatic biopsies were performed for confirmation of the results. A total of 2100 healthy males who met the inclusion criteria of the study were evaluated. The highest percentage of men with PSA4 ng ml–1 was in the age group 61–70, 51–60 years (42.7 and 31.8%, respectively). The number of subjects with an elevated PSA only was 172 (8.1%). Those having both elevated PSA and an abnormal DRE were 51 (2.4%). The total number referred to biopsy was 223. Fifty two subjects had a positive diagnosis of prostatic adenocarcinoma, which compromised 2.5% of the cohort studied. The cancer in 27 (52%) persons was organ confined, whereas in 14 (26.9%), it was metastatic. The prevalence rate of prostate cancer detected by screening was higher than expected and the disease was advanced. Larger community-based larger studies are highly warranted specially among high-risk groups.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. US Preventive Services Task Force updates Prostate Cancer Screening recommendations. 2008. http://www.acponline.org/pressroom/pcancer.htm. Accessed October 2009.

  2. National Cancer Institute. Prostate cancer screening. http://www.cancer.gov/cancertopics/pdq/screening/prostate/Patient. Accessed October 2009.

  3. AUA American new guidelines on prostate cancer screening. April 2009. http://www.psa-rising.com/mednews/component/content/article/38-screening/78-aua-new-guidelines-on-prca-screening.

  4. Smith RA, Cokkinides V, Eyre HJ . American Cancer Society Guidelines for the Early Detection of Cancer 2003. CA Cancer J Clin 2003; 53: 27–43.

    Article  Google Scholar 

  5. What does shared decision making mean for prostate screening. http://blogs.wsj.com/health/2009/09/28/what-does-shared-decision-making-mean-for-prostate-screening/. Accessed September 2009.

  6. Ministry of Health. Saudi National Cancer Registry. Cancer Incidence Report, Saudi Arabia, 2004.

  7. Vadarampil ST, Jacobsen PB, Kash K, Watson IS, Saloup R, Pow-Sang J . Factors predicting PSA testing among first degree relatives of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2004; 13: 753–758.

    Google Scholar 

  8. UK prostate cancer incidence statistics. www.info.cancerresearchuk.org/cancerstats/types/prostate/incidence/. Accessed 9/2009.

  9. Evans HS, Moller H . Recent trends in in prostate cancer incidence and mortality in Southeast England. Eur Urol 2003; 43 (4): 337–341.

    Article  Google Scholar 

  10. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate cancer mortality in a randomized European study. NEJM 2009; 360: 1320–1328.

    Article  Google Scholar 

  11. Andriole GL, Grubb RL, Crawford ED, Buys SS, Chia D, Fouad MN et al. Mortality results from a randomized prostate cancer screening trial. NEJM 2009; 360 (13): 1310–1313.

    Article  CAS  Google Scholar 

  12. Presti Jr JC, Chang JJ, Bhargava V, Shinohara K . The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: 163–167.

    Article  Google Scholar 

  13. Philip J, Hanchanale V, Foster CS, Javle P . Importance of peripheral biopsies in maximising the detection of early prostate cancer in repeat 12-core biopsy protocols. BJU Int 2006; 98: 559–562.

    Article  Google Scholar 

  14. Djavan B, Margretier M . Biopsy standards for detection of prostate cancer world. J Urol 2007; 25: 11–17.

    Google Scholar 

Download references

Acknowledgements

The study was supported by a grant from King Abdulaziz city for science and technology (KACST) and Princess Al Johara Al Ibrahim center for Cancer Research.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M A Arafa.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rabah, D., Arafa, M. Prostate cancer screening in a Saudi population: an explanatory trial study. Prostate Cancer Prostatic Dis 13, 191–194 (2010). https://doi.org/10.1038/pcan.2009.60

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.60

Keywords

This article is cited by

Search

Quick links